Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome P-450 CYP2C9

Thromb Haemost 2003; 90(01): 161-162
DOI: 10.1055/s-0037-1613616

Letters to the Editor

Schattauer GmbH

José Zarza

,

José Hermida

,

Ramón Montes

,

José Antonio Páramo

,

Eduardo Rocha

References
1 Ansell J, Hirsh J, Dalen J. et al. Managing oral anticoagulant therapy. Chest 2001; 119 (Suppl. 01) 22S-38S.
2 Levine MN, Raskob G, Landefeld S. et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119 (Suppl. 01) 108S-21S
3 Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-19.
4 Margaglione M, Colaizzo D, D’Andrea G. et al. Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost 2000; 84: 775-78.
5 Hermida J, Zarza J, Alberca I. et al. Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on acenocoumarol sensitivity. Blood 2002; 99: 4237-39.
6 Tassies D, Freire C, Pijoan J. et al. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Haematologica 2002; 87: 1185-91.
7 Higashi MK, Veenstra DL, Kondo LM. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 2002; 287: 1690-8.
8 Verstuyft C, Morin S, Robert A. et al. Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers. Pharmacogenetics 2001; 11: 735-7.
9 Kirchheiner J, Bauer S, Meineke I. et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12: 101-9.